LFSCvsETF 2ETF Comparison
VS
Choose a second ETF to run a side-by-side ETF comparison with LFSC, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
LFSC performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 07/24/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | LFSC ETF 2 | +4.17%– | +20.39%– | +23.23%– | +82.30%– | n/a– | n/a– |
| Flows | LFSC ETF 2 | +$2M– | +$3M– | +$8M– | +$17M– | -– | -– |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | LFSC ETF 2 | +26.23%– | +26.91%– | n/a– | n/a– |
| Max drawdown | LFSC ETF 2 | -6.53%– | -16.25%– | n/a– | n/a– |
| Max drawdown duration | LFSC ETF 2 | 20d– | 168d– | n/a– | n/a– |
Trading data
LFSC | ETF 2 | |
Last sale 7/24/2026 at 1:30 PM | $45.10 | – |
| Previous close 07/23/2026 | $45.46 | – |
| Consolidated volume 07/23/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Advertisement
Main metrics
Last update 7/24/2026 at 1:30 PM
Live
Closed
LFSC | ETF 2 | |
|---|---|---|
| Last price | $45.10 | – |
| 1D performance | -0.79% | – |
| AuM | $123.48 M | – |
| E/R | 0.79% | – |
Characteristics
LFSC | ETF 2 | |
|---|---|---|
| Management strategy | Active | – |
| Provider | Emerald Group | – |
| Benchmark | - | – |
| N° of holdings | 40 | – |
| Asset class | - | – |
| Trailing 12m distribution yield | Join | Join |
| Inception date | October 31, 2024 | – |
| ESG | No | – |
Advertisement
Exposure
Countries
LFSC
USA
90.9%
United Kingdom
7.04%
Other
2.06%
ETF 2
Sectors
LFSC
Healthcare
98.03%
Other
1.97%
ETF 2
Advertisement
Diversification
LFSC
Total weight of top 15 holdings out of 15
73.24%
ETF 2
–
Top 15 holdings
Data as of June 30, 2026
LFSC
Travere Therapeutics, Inc.
8.37%
Cogent Biosciences, Inc.
7.18%
LivaNova Plc
7.04%
Spyre Therapeutics, Inc.
6.71%
Guardant Health, Inc.
5.56%
Corcept Therapeutics, Inc.
5.27%
Mirum Pharmaceuticals, Inc.
5.25%
BillionToOne, Inc.
4.25%
Cytokinetics, Inc.
4.13%
Veradermics, Inc.
3.76%
United Therapeutics Corp.
3.55%
Trevi Therapeutics, Inc.
3.50%
Savara, Inc.
3.20%
Dianthus Therapeutics, Inc.
2.77%
Nektar Therapeutics
2.70%
ETF 2
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Advertisement
Advertisement
